PlumCare RWE partners with Lifebit on Greece’s newborn genomic sequencing program, BeginNGS
Lifebit, a leading UK-based precision medicine software company, was awarded a three-year contract with PlumCare RWE to support the scaling of BeginNGS Greece a pioneering newborn sequencing program.
“We are thrilled to partner with Lifebit as it will allow us to securely connect data from Greece’s first newborn screening program with global cohorts. With this, our researchers can gain crucial insights to better understand rare diseases and ultimately save lives,” said Petros Tsipouras, Chief Executive Officer at PlumCare RWE.
Worldwide, thousands of children are born with rare genetic conditions that severely affect their quality of life. For approximately 400 early onset but actionable genetic conditions, these can be detected easily using genomic sequencing and appropriate interventions given, allowing affected families to lead lives unburdened by disease.
- PlumCare RWE and Lifebit enter a three-year partnership to support Greece’s pioneering national newborn genomic sequencing program, BeginNGS.
- Researchers will be able to access and analyse data securely in combination with global cohorts, whilst ensuring data is kept safe, private and in place in their secure environment using Lifebit’s federated technology.
- This will help detect approximately 400 early onset but actionable genetic conditions in newborns, ensuring appropriate treatments can be given as early as possible, to help limit the impact of the diseases.
Beacon Capital Advisors LLP
16 Great Queen Street
London WC2B 5AH
United Kingdom
Contact Us
hello@beaconcapital.co.uk
LEGAL
Beacon Capital Advisors LLP is an Appointed Representative of The Fund Incubator Limited which is authorised and regulated by the Financial Conduct Authority FRN 208716